Skip to main content
. 2014 Jun 23;9(6):e99993. doi: 10.1371/journal.pone.0099993

Figure 7. Effect of ATO and fludarabine on MEC-1 cells.

Figure 7

(A, B) 7.5×104 MEC-1 cells in IMDM/0.1% FBS were treated or not with the indicated concentrations of ATO (A) or fludarabine (Fluda) (B). After 24 h (ATO) or 48 h (Fluda), cell viability was determined by the MTT assay. Control cell viability was normalized to 100 and average values are shown. (C,D) 5×106 MEC-1 cells were treated with 3 µM ATO for the indicated times and MMP-9 mRNA expression was analyzed by RT-PCR, using GAPDH as internal control (C) and qPCR, using TBP as internal control (D). Normalized average values (fold change) are shown. (E) 1.5×105 MEC-1 cells were treated or not with 3 µM ATO for 24 h and MMP-9 surface expression was analyzed by flow cytometry, using an anti-MMP-9 pAb or a control pAb. Histograms from a representative experiment and normalized average values for the three experiments performed are shown. White areas, control/untreated cells; grey areas, ATO-treated cells. Arrows indicate the specific fluorescence. *P≤0.05; **P≤0.01; ***P≤0.001.